Health and Healthcare
What to Expect From Valeant Pharma Q4 Earnings
Published:
Last Updated:
Valeant Pharmaceuticals International Inc. (NYSE: VRX) is scheduled to report its fourth-quarter preliminary results and update its 2016 financial guidance in a conference call Tuesday morning. The consensus estimates call for $2.61 in earnings per share (EPS) on $2.75 billion in revenue. The same period from the previous year had $2.58 in EPS on $2.28 billion in revenue.
This company has been a lightning rod for attention of late, with the CEO taking medical leave and then coming back, controversial dealings with Philidor and a presidential hopeful attacking over “predatory pricing.”
At this point, investors might be reaching for the parachute’s ripcord, or considering whether to buy in more, but one key analyst is taking a “Let’s see what happens” perspective, despite downgrading Valeant and slashing its price target.
Canaccord Genuity downgraded Valeant to a Hold rating from Buy, related to the growing uncertainty surrounding its multitude of investigations, both internal and external. This downgrade is also based on the firm’s decreasing reliance on the company’s fundamentals (drug pricing, strained managed care relationships, patent challenges to Xifaxan). The price target of Valeant was lowered to $75 from $125 as well, still implying some upside for the stock in 2016.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
